297 related articles for article (PubMed ID: 23644254)
1. Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population.
Jin TB; Ma LF; Zhang JY; Yuan DY; Sun Q; Zong TY; Geng TT; Cui YL; Kang LL; Chen C
Gene; 2013 Sep; 527(1):360-5. PubMed ID: 23644254
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms analysis of CYP2D6 in the Uygur population.
He X; He N; Ren L; Ouyang Y; Zhang N; Ma Y; Yuan D; Kang L; Jin T
BMC Genomics; 2016 May; 17():409. PubMed ID: 27228982
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese.
Zhou Q; Yu XM; Lin HB; Wang L; Yun QZ; Hu SN; Wang DM
Pharmacogenomics J; 2009 Dec; 9(6):380-94. PubMed ID: 19636337
[TBL] [Abstract][Full Text] [Related]
4. Differences in frequencies of UGT1A9, 1A7, and 1A1 genetic polymorphisms in Chinese Tibetan versus Han Chinese populations.
Yan W; Wang YW; Yang FF; Wang M; Zhang XQ; Dong J; Chen E; Yang J
Genet Mol Res; 2013 Dec; 12(4):6454-61. PubMed ID: 24390994
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of CYP2D6 in Chinese mainland.
Ji L; Pan S; Wu J; Marti-Jaun J; Hersberger M
Chin Med J (Engl); 2002 Dec; 115(12):1780-4. PubMed ID: 12622923
[TBL] [Abstract][Full Text] [Related]
6. Genetic variations of human CYP2D6 in the Chinese Han population.
Qian JC; Xu XM; Hu GX; Dai DP; Xu RA; Hu LM; Li FH; Zhang XH; Yang JF; Cai JP
Pharmacogenomics; 2013 Nov; 14(14):1731-43. PubMed ID: 24192122
[TBL] [Abstract][Full Text] [Related]
7. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population.
Buzková H; Pechandová K; Slanar O; Perlík F
Cell Biochem Funct; 2008; 26(1):76-81. PubMed ID: 17311358
[TBL] [Abstract][Full Text] [Related]
8. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Toscano C; Klein K; Blievernicht J; Schaeffeler E; Saussele T; Raimundo S; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):755-66. PubMed ID: 17001295
[TBL] [Abstract][Full Text] [Related]
9. Linkage disequilibrium mapping identifies a 390 kb region associated with CYP2D6 poor drug metabolising activity.
Hosking LK; Boyd PR; Xu CF; Nissum M; Cantone K; Purvis IJ; Khakhar R; Barnes MR; Liberwirth U; Hagen-Mann K; Ehm MG; Riley JH
Pharmacogenomics J; 2002; 2(3):165-75. PubMed ID: 12082588
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism analysis of the drug-metabolizing enzyme CYP2C9 in a Chinese Tibetan population.
Jin T; Geng T; He N; Shi X; Wang L; Yuan D; Kang L
Gene; 2015 Aug; 567(2):196-200. PubMed ID: 25958051
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
13. The frequencies of mutated alleles of CYP2D6 gene in a Turkish population.
Serin A; Canan H; Alper B; Gulmen M
Forensic Sci Int; 2012 Oct; 222(1-3):332-4. PubMed ID: 22910059
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities.
Bagheri A; Kamalidehghan B; Haghshenas M; Azadfar P; Akbari L; Sangtarash MH; Vejdandoust F; Ahmadipour F; Meng GY; Houshmand M
Drug Des Devel Ther; 2015; 9():2627-34. PubMed ID: 25999696
[TBL] [Abstract][Full Text] [Related]
16. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity.
Wang D; Poi MJ; Sun X; Gaedigk A; Leeder JS; Sadee W
Hum Mol Genet; 2014 Jan; 23(1):268-78. PubMed ID: 23985325
[TBL] [Abstract][Full Text] [Related]
17. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
18. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
[TBL] [Abstract][Full Text] [Related]
19. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
20. Genotype‑phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapy.
Jin T; Zhang X; Geng T; Shi X; Wang L; Yuan D; Kang L
Mol Med Rep; 2016 Mar; 13(3):2117-23. PubMed ID: 26781306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
